Introduction: Comprehensive molecular profiling of CRC can inform treatment decisions by identifying patient subgroups at varying risks of death. Microsatellite instability (MSI) is prognostic in CRC and is used to select patients for immunotherapy. High tumor mutational burden (TMB) is associated with genomic instability and is prognostic in melanoma. Expression of p16 protein is prognostic in many tumor types. We used proteomic and genomic profiling to measure MSI, TMB and p16 in CRC tumors and to assess associations with patient survival. The global proteome data was also used to identify potentially prognostic protein biomarkers.
https://ift.tt/2K4VLCp
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου